article
This webinar, held on 28 June 2018, illustrated the optimisation…
7 September 2018 | By DiscoverX Corporation, Eurofins Pharma Discovery Services
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.